Exact Sciences Corporation (FRA:EXK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 16.49B |
| Revenue (ttm) | 2.63B |
| Net Income (ttm) | -840.86M |
| Shares Out | n/a |
| EPS (ttm) | -4.49 |
| PE Ratio | n/a |
| Forward PE | 119.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 85 |
| Open | 86.42 |
| Previous Close | 86.44 |
| Day's Range | 86.42 - 86.42 |
| 52-Week Range | 33.80 - 88.16 |
| Beta | n/a |
| RSI | 82.95 |
| Earnings Date | Feb 17, 2026 |
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri... [Read more]
Financial Performance
In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.
Financial numbers in USD Financial StatementsNews
Noteworthy ETF Inflows: XBI, EXAS, RVMD, RNA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approxima...
Top 2 Health Care Stocks You May Want To Dump This Month
As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
$100 Invested In Exact Sciences 15 Years Ago Would Be Worth This Much Today
Exact Sciences (NASDAQ: EXAS) has outperformed the market over the past 15 years by 9.5% on an annualized basis producing an average annual return of 21.58%. Currently, Exact Sciences has a market ca...
Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 15 Years
Exact Sciences (NASDAQ: EXAS) has outperformed the market over the past 15 years by 8.51% on an annualized basis producing an average annual return of 20.65%. Currently, Exact Sciences has a market c...
EXAS Quantitative Stock Analysis
Below is Validea's guru fundamental report for EXACT SCIENCES CORP (EXAS). Of the 22 guru strategies we follow, EXAS rates highest using our P/B Growth Investor model based on the published strategy o...
This Coinbase Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Exact Sciences (EXAS) Downgraded by Canaccord Genuity, PT Raised to $105 | EXAS Stock News
Exact Sciences (EXAS) Downgraded by Canaccord Genuity, PT Raised to $105 | EXAS Stock News
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More
Pre-Market Stock Futures: The futures are lower on Tuesday after traders kicked off the holiday-shortened trading week with a massive Monday rally, with all major indices finishing the day higher. A c...
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts across its Precision Oncology portfolio at t...
Exact Sciences (EXAS) Downgraded to Hold by Benchmark Analyst | EXAS Stock News
Exact Sciences (EXAS) Downgraded to Hold by Benchmark Analyst | EXAS Stock News
EXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott Laboratories
MONSEY, N.Y., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Exact Sciences Corporation (Nasdaq: EXAS) (“Exact Sciences”) t...
Here are Monday’s Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More
Pre-Market Stock Futures: The shortened holiday week is here, and the futures are trading higher this morning. Most traders and investors are returning with a severe case of whiplash after the stock m...
Exact Sciences (EXAS) Receives Downgrade from Jefferies Amidst Price Target Increase | EXAS ...
Exact Sciences (EXAS) Receives Downgrade from Jefferies Amidst Price Target Increase | EXAS Stock News
Abbotts $21 Billion Exact Sciences Deal Fills Void Of Lost Covid Test Sales
Abbotts $21 Billion Exact Sciences Deal Fills Void Of Lost Covid Test Sales
Exact Sciences (EXAS) Shares Surge on Abbott Acquisition Deal
Exact Sciences (EXAS) Shares Surge on Abbott Acquisition Deal
Alphabet, Exact Sciences, And Regeneron Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 17-Nov. 21): Are the Others in Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio ? Exact Sciences Corporation (NASDAQ: EXAS) gained 48.97% this week after Abbott Laboratories (NYSE: ABT)a...
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact...
Abbott Laboratories: Not Passing The Test, After Buying Test Maker Exact Sciences
Abbott's $23B Exact Sciences deal adds short-term risk and earnings dilution. Read what this means for investors and when value could improve.
Exact Sciences (EXAS): Wells Fargo Downgrades Rating, Raises Price Target | EXAS Stock News
Exact Sciences (EXAS): Wells Fargo Downgrades Rating, Raises Price Target | EXAS Stock News
Exact Sciences (EXAS) Receives Downgrade from William Blair | EXAS Stock News
Exact Sciences (EXAS) Receives Downgrade from William Blair | EXAS Stock News
Exact Sciences (EXAS) Downgraded to Neutral by Guggenheim | EXAS Stock News
Exact Sciences (EXAS) Downgraded to Neutral by Guggenheim | EXAS Stock News
EXAS: Barclays Downgrades Exact Sciences, Raises Price Target to $105 | EXAS Stock News
EXAS: Barclays Downgrades Exact Sciences, Raises Price Target to $105 | EXAS Stock News
Here Are Friday’s Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More
Pre-Market Stock Futures:The futures are trading higher as we get ready to close out a volatility-filled week that saw a massive roller coaster ride on Thursday after NVIDIA Corp. (NASDAQ: NVDA) earni...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1372891929-1fc39a3b97984d12bebebf9567b6a270.jpg)
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday
Shares of Exact Sciences Corp. jumped after Abbott Laboratories announced a deal to acquire the cancer screening test maker for about $21 billion.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Exact Sciences Corporation (NASDAQ: EXAS)
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and ...